Live Analyst Rating Changes 23667 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ryan Halsted
RBC

Ryan Halsted

RBC Capital
Wall Street Analyst
★★★★☆
#606
on 13Foresight · ranked by our own returns
64%
Success Rate
+4.8%
Average Return
28 of 44 calls profitable · +1.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 64% of Ryan Halsted's ratings turned a profit when each position was held for 1 year — averaging +4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

71 Buy 16 Hold 0 Sell
Ryan's Stock Coverage 17 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
DOCS
Doximity
 Aug 06, 2026 BUY Buy
+37.3% avg upside
28 analysts
$28.00
7.20% Upside
 +21.0% ·
PRVA
Privia Health Group
 Aug 06, 2026 BUY Strong Buy
+47.3% avg upside
26 analysts
$31.00
41.11% Upside
 +1.7% ·
SHC
Sotera Health
 Aug 06, 2026 BUY Strong Buy
+16.6% avg upside
13 analysts
$24.00
25.57% Upside
 -0.1% ·
EVH
Evolent Health
 Aug 06, 2026 HOLD Strong Buy
+130.3% avg upside
19 analysts
$3.00
26.80% Downside
 +17.5% ·
CRL
Charles River Labs
 Aug 05, 2026 BUY Strong Buy
-17.2% avg upside
35 analysts
$282.00
0.06% Upside
 +9.1% ·
MDLN
Medline
 Aug 05, 2026 BUY Strong Buy
+32.3% avg upside
27 analysts
$46.00
31.35% Upside
 -3.2% ·
ICLR
Icon
 Jul 30, 2026 BUY Strong Buy
+12.7% avg upside
26 analysts
$185.00
11.78% Upside
 +1.0% ·
WAY
Waystar Holding Corp.
 Jul 29, 2026 BUY Strong Buy
+51.7% avg upside
30 analysts
$44.00
81.17% Upside
 +0.1% ·
IQV
IQVIA Holdings
 Jul 28, 2026 BUY Strong Buy
+1.4% avg upside
39 analysts
$247.00
1.35% Upside
 -0.5% ·
MEDP
Medpace Holdings
 Jul 23, 2026 BUY Buy
-19.0% avg upside
17 analysts
$692.00
14.25% Upside
 -1.1% ·
HCSG
Healthcare Services
 Jul 22, 2026 HOLD Buy
+16.9% avg upside
12 analysts
$24.00
14.46% Upside
 -6.4% ·
HQY
Healthequity
 Jul 08, 2026 BUY Strong Buy
+7.9% avg upside
20 analysts
$108.00
2.29% Upside
 +11.4% ·
PHR
Phreesia
 May 27, 2026 BUY Strong Buy
+39.3% avg upside
21 analysts
$19.00
54.78% Upside
 +25.9% ·
BKD
Brookdale Senior Living
 Jan 12, 2017 BUY Strong Buy
+8.7% avg upside
11 analysts
 — -40.5% ·
SNDA
Sonida Senior Living
 Oct 06, 2016 HOLD Buy
+122.3% avg upside
13 analysts
 — -18.6% ·
SCI
Service International
 Sep 09, 2016 HOLD Strong Buy
+20.3% avg upside
9 analysts
 — +35.2% ·
ENSG
The Ensign Group
 May 12, 2016 HOLD Strong Buy
-8.2% avg upside
9 analysts
$21.50
88.10% Downside
 -4.4% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ryan Halsted — Frequently Asked Questions
How accurate are Ryan Halsted's stock ratings?
Based on the calls 13Foresight could measure, about 64% of Ryan's ratings were profitable over a one-year hold, with an average return of +4.8% per rating, or +1.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Ryan ranked on 13Foresight?
Ryan Halsted is currently ranked #606 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ryan cover?
Ryan most recently has ratings on DOCS, PRVA, SHC, EVH, CRL, MDLN, ICLR, WAY, IQV, MEDP, HCSG, HQY and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.